



SUGGESTED FORMULA

Levothyroxine Sodium (T4) 47.5 mcg /Liothyronine (T3) 11.25 mcg Slow-Release Capsules

Version number: 1.0

Volume or quantity: 100 capsules

Levothyroxine Sodium (T4) 1:1000 Aliquot for compounding	4.75gm
Liothyronine Sodium (T3) 1:1000 Aliquot for compounding	1.125g,
Hypromellose, Sub Type 2910, 4000 mPa.S, USP (H1128)	10g
Microcrystalline Cellulose, NF (C1679)	12.875gm
Colloidal Silicon Dioxide (Silica Gel) Micronized	0.100gm

*It is necessary to determine the quantity of active drug and calibrate empty capsules prior to beginning the preparation of this formula.

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared.
2. Accurately weigh and/or measure each ingredient.
3. Triturate to reduce to fine powders as needed
4. Mix powders per pharmacy SOPs – (e.g. geometric dilution, blade, v-blend, RAM™) – thorough mixing is critical for preparation potency
5. Fill capsules in vented enclosure (hood)
6. Cap and “snap” each bottom into its lid.
7. Weigh sample capsules to check variability and standard deviation per pharmacy SOPs
8. Bottle and label with prescription label and appropriate auxiliary labels.
9. Suggested Quality assessments
 - a. % variability & % deviation from theoretical <10% - (remake if >10%)
 - b. Capsule size
 - c. Capsule color
 - d. Quantity
 - e. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at Controlled room temperature

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products,

organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date estimated to be 180 days or as directed by the current USP <795>

Precautions:

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.

8/19RD

Phone: 800.370.6231 | Fax: 732.608.5420 | Internet: SpectrumRx.com | Email: sales@spectrumrx.com
© 2015 Spectrum Pharmacy Products. All rights reserved.

